Post-renovation BioPort Production

FDA Lot-Release Authorizations

These memos show the authority for the manufacturer to release anthrax vaccine from the manufacturing plant. Each lot of every vaccine produced in the United States must be individually released in this way, after having been tested for sterility, purity, potency, and general safety. Lot-release tests are performed by the manufacturer and audited by FDA.

Show Current content only Show Archived content only Show All
	FAV114 PDF  17 Mar 05  FAV113 PDF  22 Feb 05  FAV112 PDF  15 Feb 05  FAV111 PDF  17 Mar 05  FAV110 PDF  30 Dec 04  more...  *For Anthrax vaccine released after January 2002 (Lots FAV063 and higher)